Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33377526

about

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Multiple myeloma Elotuzumab for the treatment of multiple myeloma Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Chemotherapy-induced peripheral neuropathy: an update on the current understanding Treatment of relapsed and refractory multiple myeloma Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma Current and emerging treatment options for patients with relapsed myeloma From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)New criteria for response assessment: role of minimal residual disease in multiple myeloma The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective Recent advances in multiple myeloma: a Korean perspective Cost-effectiveness of bortezomib for multiple myeloma: a systematic review Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Review of health-related quality of life data in multiple myeloma patients treated with novel agents."Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.Treatment of multiple myeloma bone disease: experimental and clinical data.Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.Pomalidomide is active in the treatment of anemia associated with myelofibrosis

P2860

Q21133524-7B0A00C4-DF68-4C0A-A10A-F406D6E9DA14 Q21285161-EE1E9DD0-4CF6-483B-9BA3-2B45A734E1E7 Q24655964-422B7A16-BB78-49E0-831F-1DCD0D37FCD6 Q26740278-97D6F8D5-392E-4DD8-B169-E9ABB2DD3081 Q26740359-E1DD2262-9C11-4C16-85A9-9AB8267FD4E3 Q26740689-5510C09E-FEAD-4291-84FD-D608E2C5D272 Q26749180-ABF3DE18-14D7-4C00-8BB3-C512780FC056 Q26766718-2AF010F1-5002-431C-BDA4-9B63259E32F0 Q26771331-75402435-F7C7-453E-86D1-BEA90795816F Q26782868-1D349F4E-6AC8-41DA-BE6A-A0B3EB5FC54E Q26785497-2B42FF6F-0ACB-43B7-834F-BF481EAB4B3F Q26822754-CAF9475F-057E-4733-A8A5-79DCDC8E6085 Q26823292-B27C26B0-0A51-4F50-BE3A-2E1705299191 Q26830878-1807F577-5615-485D-8EF1-CA8063A3E506 Q26862828-E0530DFA-B021-4E9C-8311-E0F8032E7545 Q26992002-3739F1F2-C3E7-45E3-8015-7503D5C09753 Q26998884-84A30714-2DE2-4B6B-9871-04B8F84033F8 Q27002668-AFEA9925-49A9-498C-A332-793029C36E6F Q27004421-BB94D89D-C2DC-4B21-A960-D58813BCBD6D Q27027512-5243F89C-B0AD-4FEE-B86A-CCDD0F4141E1 Q28069789-23F33214-3C81-4B65-8A82-F1D247E7A806 Q28074521-3BF8B0DA-4443-4C3D-86A7-140A1B3129FE Q28075297-F4260FB5-DB8B-4B3B-8A98-1D662FF49298 Q28076147-4EC4CEAF-9379-4EAB-AF19-BB3CDC4A1679 Q28478936-62DD4C1E-1690-491E-9010-413B9AFDBCAF Q28483760-D657663B-0CE4-4D40-B4BF-DF59043672F0 Q28534997-0277C676-D18B-4A6C-8D7E-8A2905611B6C Q28537997-24410AEC-D7CC-4504-9C2B-EC892EB12D50 Q28551480-47CA76FE-C66C-4B55-9EF4-442259C154AE Q30238893-6955B28A-515E-4AA7-8484-590052BD76CF Q30249513-4D56F766-F715-41A0-AE58-A844D2F475AF Q30275870-08049139-8733-4B71-8DF4-D681B0647DB2 Q30358639-14F85A28-0644-4CED-9387-D8C845A0ACF2 Q30433139-C37B9441-DC2B-4875-97C7-839D47625DDB Q30650394-DE5A1A2E-D6B2-46D5-8A4B-5C6498CC7601 Q30657752-38A84B8E-0B5F-4F47-A516-03904CF8873B Q30669943-CCD9BAD3-97F3-40DE-93A0-BE4148ADC608 Q30868833-CFAA968A-CEAE-4CB6-A9D5-6CDF21DCD73C Q33385308-078FCF56-CA1A-4FB4-A813-CE9D422E3CF2 Q33385644-E62AEE9C-0538-4087-981E-ED70316CFC01

P2860

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33377526

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

@ast

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

@en

type

label

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

@ast

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

@en

prefLabel

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

@ast

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

@en

P1433

Q33377526-FEFE7E81-421F-487F-B275-5E9874B097C1

P1476

Q33377526-9B4F2EF2-F700-40C0-A5BB-93F1FE75A50F

P2093

Q33377526-0C95E345-29DC-4BC5-A7BB-4F7080186BCC

Q33377526-11B709D1-CDDD-4C87-8D8F-06F4AC0CDE27

Q33377526-142E7B2A-04D5-4A63-947B-2B7E4BB03C34

Q33377526-2A97B1E5-6D0D-41F4-A736-21BC522BDDB4

Q33377526-2BB94568-F6AC-457B-BF6B-FE94CC7A3906

Q33377526-451177F9-7940-4558-AF8E-D7675E1B9DD7

Q33377526-47F980F5-6792-4D33-9930-76B69363EF4C

Q33377526-498346A0-6F7B-41F0-84CC-5C73BC8AC8BE

Q33377526-5ACC748B-4560-4010-A719-921BD17F7A1A

Q33377526-A6BB4E66-7573-41F4-B2F8-E0A802538EFC

P304

Q33377526-D2C1CDB8-1B43-437F-8E6D-8F8F4B6FD633

P31

Q33377526-B7CAC114-3AC1-4C3D-A824-EE52F0448E87

P356

Q33377526-740CD641-43FF-4BC8-8740-1D2D513FACC6

P407

Q33377526-7937FB2F-4FC3-44B0-8407-3B65C9E1FCC6

P433

Q33377526-A8470E8E-2464-4384-9408-6A339C70187F

P478

Q33377526-46B8A13D-88F6-4419-9C28-5499020B19DA

P50

Q33377526-38335362-DAD8-4811-B7F8-FB0AD42D2FC4

Q33377526-3DCDA80E-D1D1-4CE5-B136-A0394E90788B

Q33377526-7314881B-3AC8-4707-8A29-306667D8ADC7

Q33377526-E42B431C-917B-41AD-A42D-12DB93583E72

Q33377526-F58929BE-9BDC-4475-B157-717B08EDF58C

P577

Q33377526-10F24D1F-0F1E-4B54-B9F7-B3985AF0688B

P698

Q33377526-1D5C3F99-8AF4-4E70-BAFA-7B6A38790F5E

P921

Q33377526-1A4C35AA-3DED-4892-9F29-B8A2F580CD45

P356

P1433

The New England Journal of Medicine

P1476

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

@en

P2093

Alessandro Corso

http://www.w3.org/2001/XMLSchema#string

Andrew Spencer

http://www.w3.org/2001/XMLSchema#string

Andrzej Hellmann

http://www.w3.org/2001/XMLSchema#string

H Miles Prince

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Harousseau

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

John Patin

http://www.w3.org/2001/XMLSchema#string

Marta Olesnyckyj

http://www.w3.org/2001/XMLSchema#string

Michael Attal

http://www.w3.org/2001/XMLSchema#string

Multiple Myeloma (010) Study Investigators

http://www.w3.org/2001/XMLSchema#string

P304

2123-2132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA070594

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Jesus San Miguel

Anna Dmoszyńska

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18032762

http://www.w3.org/2001/XMLSchema#string

P921